Nearly 15% of Medicare Part B enrollees pay the full 20% coinsurance for their reference biologic, while others have supplemental insurance that only covers a portion of the 20%.
A group of 16 advocacy groups are urging HHS to make zero co-pays for biologics a part of its prescription drug price reform program.
As the deadline approaches for HHS to divulge its game plan for controlling prescription drug costs and “price gouging,” levels of concern are rising among providers and manufacturers.
A group of 16 patient advocacy organizations has asked CMS and HHS to consider establishing a zero co-pay policy for Medicare Part B patients, a move the groups said would improve access to biosimilars and save seniors in Medicare as much as $3 billion in out-of-pocket costs.
“Alignment of incentives across Medicare programs that encourage the use of biosimilars are integral to the development of the US market, leading to increased biosimilar usage and unlocking immense savings in the US health care system,” the group said in an open letter to HHS and CMS officials.
The letter was signed by the Allergy & Asthma Network, CancerCare, Consumer Action, Crohn’s & Colitis Foundation, Endocrine Society, Healthy Women,, International Myeloma Foundation, Lupus Foundation of America, and others.
President Biden has directed HHS to produce a policy for combating high prescription drug prices as soon as Monday, August 23.
The advocacy groups, in their letter, acknowledge the high cost of biologics, which are made from living organisms and require extensive, carefully controlled processes to develop and manufacture.
Biosimilars are lower-cost alternatives to originator biologics and have no clinically meaningful differences when it comes to safety or efficacy, according to the FDA. “These therapies represent an opportunity to improve the health and well-being of millions of Americans and, at the same time, save US taxpayers billions in health care costs," the advocacy groups said.
Nearly 15% of Medicare Part B enrollees pay the full 20% coinsurance for their reference biologic, while others have supplemental insurance that only covers a portion of the 20%.
US patients have had access to biosimilars for 6 years; 30 of them are now approved and 21 are on the market. Medicare “enrollees can face thousands of dollars in annual out-of-pocket costs for biologics, creating affordability and access barriers for patients in Part B. Nearly 15% of Medicare Part B enrollees pay the full 20% coinsurance for their reference biologic, while others have supplemental insurance that only covers a portion of the 20%,” the letter states.
The group estimates that a zero co-pay policy would save taxpayers $5 billion over 10 years.
Other signatories to the letter included Beyond Type 1, DiabetesSisters, National Consumers League, Patients Rising Now, Rheumatology Nurses Society, Sjögren’s Foundation, and ZERO - The End of Prostate Cancer.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.